Cargando…

Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome

OBJECTIVES: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wind, Merlijn, Hendriks, Maike, van Brussel, Bernadette T J, Eikenboom, Jeroen, Allaart, Cornelia F, Lamb, Hildo J, Siebelink, Hans-Marc J, Ninaber, Maarten K, van Geloven, Nan, van Lith, Jan M M, Huizinga, Tom W J, Rabelink, Ton J, Sueters, Marieke, Teng, Y K Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103373/
https://www.ncbi.nlm.nih.gov/pubmed/33952625
http://dx.doi.org/10.1136/lupus-2020-000472
_version_ 1783689299103842304
author Wind, Merlijn
Hendriks, Maike
van Brussel, Bernadette T J
Eikenboom, Jeroen
Allaart, Cornelia F
Lamb, Hildo J
Siebelink, Hans-Marc J
Ninaber, Maarten K
van Geloven, Nan
van Lith, Jan M M
Huizinga, Tom W J
Rabelink, Ton J
Sueters, Marieke
Teng, Y K Onno
author_facet Wind, Merlijn
Hendriks, Maike
van Brussel, Bernadette T J
Eikenboom, Jeroen
Allaart, Cornelia F
Lamb, Hildo J
Siebelink, Hans-Marc J
Ninaber, Maarten K
van Geloven, Nan
van Lith, Jan M M
Huizinga, Tom W J
Rabelink, Ton J
Sueters, Marieke
Teng, Y K Onno
author_sort Wind, Merlijn
collection PubMed
description OBJECTIVES: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that patients with SLE/APS should receive multidisciplinary counselling before getting pregnant. We investigated the clinical effectiveness of implementing a multidisciplinary clinical pathway including prepregnancy counselling of patients with SLE/APS. METHODS: A clinical pathway with specific evaluation and prepregnancy counselling for patients with SLE/APS was developed and implemented in a tertiary, academic hospital setting. Patients were prospectively managed within the clinical pathway from 2014 onwards and compared with a retrospective cohort of patients that was not managed in a clinical pathway. Primary outcome was a combined outcome of disease flares for SLE and thromboembolic events for APS. Secondary outcomes were maternal and fetal pregnancy complications. RESULTS: Seventy-eight patients with 112 pregnancies were included in this study. The primary combined outcome was significantly lower in the pathway cohort (adjusted OR (aOR) 0.20 (95% CI 0.06 to 0.75)) which was predominantly determined by a fivefold risk reduction of SLE flares (aOR 0.22 (95% CI 0.04 to 1.09)). Maternal and fetal pregnancy complications were not different between the cohorts (respectively, aOR 0.91 (95% CI 0.38 to 2.17) and aOR 1.26 (95% CI 0.55 to 2.88)). CONCLUSIONS: The outcomes of this study suggest that patients with SLE/APS with a pregnancy wish benefit from a multidisciplinary clinical pathway including prepregnancy counselling.
format Online
Article
Text
id pubmed-8103373
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81033732021-05-24 Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome Wind, Merlijn Hendriks, Maike van Brussel, Bernadette T J Eikenboom, Jeroen Allaart, Cornelia F Lamb, Hildo J Siebelink, Hans-Marc J Ninaber, Maarten K van Geloven, Nan van Lith, Jan M M Huizinga, Tom W J Rabelink, Ton J Sueters, Marieke Teng, Y K Onno Lupus Sci Med Reproductive health and APS OBJECTIVES: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that patients with SLE/APS should receive multidisciplinary counselling before getting pregnant. We investigated the clinical effectiveness of implementing a multidisciplinary clinical pathway including prepregnancy counselling of patients with SLE/APS. METHODS: A clinical pathway with specific evaluation and prepregnancy counselling for patients with SLE/APS was developed and implemented in a tertiary, academic hospital setting. Patients were prospectively managed within the clinical pathway from 2014 onwards and compared with a retrospective cohort of patients that was not managed in a clinical pathway. Primary outcome was a combined outcome of disease flares for SLE and thromboembolic events for APS. Secondary outcomes were maternal and fetal pregnancy complications. RESULTS: Seventy-eight patients with 112 pregnancies were included in this study. The primary combined outcome was significantly lower in the pathway cohort (adjusted OR (aOR) 0.20 (95% CI 0.06 to 0.75)) which was predominantly determined by a fivefold risk reduction of SLE flares (aOR 0.22 (95% CI 0.04 to 1.09)). Maternal and fetal pregnancy complications were not different between the cohorts (respectively, aOR 0.91 (95% CI 0.38 to 2.17) and aOR 1.26 (95% CI 0.55 to 2.88)). CONCLUSIONS: The outcomes of this study suggest that patients with SLE/APS with a pregnancy wish benefit from a multidisciplinary clinical pathway including prepregnancy counselling. BMJ Publishing Group 2021-05-05 /pmc/articles/PMC8103373/ /pubmed/33952625 http://dx.doi.org/10.1136/lupus-2020-000472 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Reproductive health and APS
Wind, Merlijn
Hendriks, Maike
van Brussel, Bernadette T J
Eikenboom, Jeroen
Allaart, Cornelia F
Lamb, Hildo J
Siebelink, Hans-Marc J
Ninaber, Maarten K
van Geloven, Nan
van Lith, Jan M M
Huizinga, Tom W J
Rabelink, Ton J
Sueters, Marieke
Teng, Y K Onno
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
title Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
title_full Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
title_fullStr Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
title_full_unstemmed Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
title_short Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
title_sort effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
topic Reproductive health and APS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103373/
https://www.ncbi.nlm.nih.gov/pubmed/33952625
http://dx.doi.org/10.1136/lupus-2020-000472
work_keys_str_mv AT windmerlijn effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT hendriksmaike effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT vanbrusselbernadettetj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT eikenboomjeroen effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT allaartcorneliaf effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT lambhildoj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT siebelinkhansmarcj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT ninabermaartenk effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT vangelovennan effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT vanlithjanmm effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT huizingatomwj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT rabelinktonj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT suetersmarieke effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome
AT tengykonno effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome